Clinical Colorectal Cancer 2006, 5: 422–428 CrossRefPubMed 23 Ha

Clinical Colorectal Cancer 2006, 5: 422–428.CrossRefPubMed 23. Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Janne PA, Bonomi P: Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006, 24: 5253–5258.CrossRefPubMed 24. Herbst RS, Arquette M, Shin DM,

Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005, 23: 5578–5587.CrossRefPubMed 25. Hofheinz R, Horisberger K, Woernle C, Wenz F, Kraus-Tiefenbacher U, Kahler G, Dinter D, Grobholz R, Heeger

S, Post S, Hochhaus A, Willeke F: Phase I trial cetuximab in combination with AT9283 capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int Journal Radiation Oncology Biol Phys 2006, 66: 1384–1390.CrossRef 26. Ibrahim E, Zeeneldin A, Al-Gahmi A, Sallam Y, Fawzi E, Bahadur Y: Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer. Indian J Cancer 2007, 44: 56–61.CrossRefPubMed 27. Jonker D, O’Callaghan C, Karapetis C, Zalcberg J, Tu D, Au H, Berry S, Krahn M, Price T, Simes R, Tebbutt N, van Hazel G, Wierzbicki R, Langer C, Moore Protein kinase N1 M: Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine 2007, 357: 2040–2048.CrossRefPubMed 28. Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Quizartinib Spriggs DR, Aghajanian CA: A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol 2008, 110: 140–145.CrossRefPubMed

29. Koo D, Lee J, Kim T, Chang H, Ryu M, Lee S, Kim M, Sym S, Lee J, Kang Y: A phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. J Korean Med Sci 2007, 22: S98-S103.CrossRefPubMed 30. Lenz H, Van Cutsem E, Khambata-Ford S, Mayer R, Gold P, Stella P, Mirtsching B, Cohn A, Pippas A, Azarnia N, Tsuchihashi Z, Mauro D, Rowinsky E: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clinical Oncology 2006, 24: 4914–4921.CrossRef 31. Machiels JP, Sempoux C, Scalliet P, Coche JC, Humblet Y, Van CE, Kerger J, Canon JL, Peeters M, Aydin S, Laurent S, Kartheuser A, Coster B, Roels S, Daisne JF, Honhon B, Duck L, Kirkove C, Bonny MA, Haustermans K: Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>